A Case Report on the Outcome of Infantile Pompe Disease

Document Type : Case Report

Authors

1 Children Growth Disorder Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Department of Pediatrics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4 Cardiovascular Research Center, Non-communicable Diseases Research Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

5 Department of Pediatrics, Naein Heshmatie Hospital, Naein, Iran

Abstract

Background: Pompe disease, or glycogen storage disease Type II, is an autosomal recessive disorder caused by a deficiency of acid α-1,4-glucosidase, leading to lysosomal glycogen accumulation in muscle tissues. Infantile Pompe disease (IPD) typically presents within the first weeks of life and is often fatal without enzyme replacement therapy (ERT). This report details the clinical course and outcome of a seven-month-old male diagnosed with IPD.
Case Presentation: A seven-month-old male infant, born full-term to consanguineous parents, was admitted due to a severe respiratory infection. Clinical features included hypotonia, swallowing difficulties, and failure to thrive (weight: 6 kg, <5th percentile). Laboratory tests showed elevated SGOT (95), SGPT (235), and CPK (700). An ECG revealed a short PR interval and prolonged QRS duration. Echocardiography indicated severe hypertrophic cardiomyopathy with systolic dysfunction. Enzyme assays confirmed critically low α-1,4-glucosidase levels (0.1 μmol/L/h), and genetic testing identified a homozygous mutation (c.1942 G > C), confirming Pompe disease. The infant passed away before ERT could be initiated. 
Conclusion: This case highlights the challenges in diagnosing and managing Pompe disease in infants. The child's symptoms and lab results indicated a metabolic disorder, underscoring the multisystem impact of IPD. Rapid disease progression and consanguinity were significant factors. The delayed diagnosis led to a tragic outcome, emphasizing the need for early recognition and intervention. Timely ERT is crucial, as IPD can be fatal without it. This case underscores the importance of increased awareness and improved diagnostic protocols, particularly in consanguineous families and atypical presentations. Early diagnosis and intervention are essential for better outcomes.  

Keywords

Corresponding Author: Parisa Sadat Fakhimpour

View Orcid in Profile
You can search for this author in PubMed     Google Scholar Profile

References

  1. Dos Santos OCC, Schultz R. The infantile-onset form of Pompe disease: an autopsy diagnosis. Autops Case Reports 2015; 5(4): 45-51.
  2. Morales A, Poling MI, Páez MT, Cabrera J, McCormick RJ. c.1437G>A intron 9 substitution on acid α-glucosidase gene associated with classic infantile-onset Pompe disease phenotype. BMJ Case Rep 2015; 2015: bcr2015210688.
  3. Kliegman R, St. Geme JW. Nelson textbook of pediatrics. Amsterdam, Netherlands: Elsevier; 2024; 1. p. 8–22.
  4. Nyhan WL, Hoffmann GF. Atlas of Inherited Metabolic Diseases. 4th ed. Boca Raton, Fl: CRC Press; 2020.
  5. Moschetti M, Lo Curto A, Giacomarra M, Francofonte D, Zizzo C, Messina E, et al. Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study. Int J Mol Sci 2024; 25(17): 9139.
  6. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY) 2020; 12(15): 15856–74.
  7. Elenga N, Verloes A, Mrsic Y, Basurko C, Schaub R, Cuadro-Alvarez E, et al. Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open 2018; 2(1): e000182.
  8. Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis 2016; 39(2): 261–71.
  9. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A RA. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 2012; 160C(1): 59–68.
  10. Pittis MG, Donnarumma M, Montalvo AL, Dominissini S, Kroos M, Rosano C, et al. Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease. Hum Mutat 2008; 29(6): E27-36.
  11. Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007; 17(9–10): 698–706.
  12. Flanagan JJ, Rossi B, Tang K, Wu X, Mascioli K, Donaudy F, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 2009; 30(12): 1683–92.
World Journal of Peri and Neonatology
Volume 7, Issue 1
December 2024
Pages 51-55

Files

History

  • Receive Date: 21 December 2024
  • Accept Date: 21 December 2024

Share

How to cite

Statistics